-
Ebb & Flow Legal tracks Michele Frank, Toni-Junelle Herbert and Mark Shanks joined Venable LLP as partners in its patent prosecution and litigation practice. The former Patton Boggs partners represent biotech, …
Published on 1/30/2012
-
Ebb & Flow Middleman ChemoCentryx Inc. set a mid-range valuation among the would-be IPO class of 2012 when the autoimmune and cancer company announced a price range of $14.-$16. It hopes to sell 4 million shares …
Published on 1/30/2012
-
A rare investment Money Raised in 2012 Last week, the biotech industry raised $154 million, bringing to $3.4 billion the total raised year-to-date. In 2011, a total of $49 billion was raised, including $36.7 billion…
Published on 1/30/2012
-
A rare investment Earnings on deck At least 21 profitable biotechs and pharmas are slated to report earnings this week. Seven are anticipated to post 4Q11 EPS growth of 10% or more, including 16% growth by …
Published on 1/30/2012
-
A rare investment EPS watch At least 10 profitable biotechs and pharmas reported earnings last week. Four companies - Abbott Laboratories (NYSE:ABT), Amgen Inc. (NASDAQ:AMGN), Bristol-Myers Squibb Co. (NYSE:BMY) and…
Published on 1/30/2012
-
Ebb & Flow Euronext door opener The first European biotech IPO of 2012 looks to be French polymer play Adocia S.A.S., which announced details of its deal on Euronext Paris and a private placement outside the U.S. …
Published on 1/30/2012
-
Ebb & Flow A rare investment By Stephen Hansen Figure: Money Raised in 2012 Table: Earnings on deck Table: EPS watch New Enterprise Associates made its first biotech investment in Europe last week by leading a €…
Published on 1/30/2012
-
Ebb & Flow Regulatory milestones Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) was off $0.03 to $0.77 last week after FDA extended the PDUFA date for an NDA for inhaled Adasuve Staccato loxapine by three months to May 4…
Published on 1/30/2012
-
Ebb & Flow Small stakes The top two contenders for the Republican presidential nomination disclosed their 2011 tax returns last week, revealing that both Newt Gingrich and Mitt Romney owned modest holdings in the …
Published on 1/30/2012
-
Ebb & Flow Vera good reception Verastem Inc. (NASDAQ:VSTM) raised $55 million through the sale of 5.5 million shares at $10 in a bumped-up IPO, becoming the first U.S. biotech to price an IPO this year. The deal …
Published on 1/30/2012
-
VCs received M&A proceeds that outstripped their dollars invested in biotech in 2011, and also exceeded the new money raised by venture firms.
Published on 1/23/2012
-
Ebb & Flow Venture tracks Bay City Capital promoted Min Cui to partner from principal. The firm has $1.6 billion under management. --Michael Flanagan
Published on 1/23/2012
-
Ebb & Flow Valuing Verastem Three companies in the IPO queue have set their price ranges this month, providing valuation benchmarks for other biotechs looking to go public in 2012. The real question is whether …
Published on 1/23/2012
-
Forma-tive thinking Money Raised in 2012 Last week, the biotech industry raised $2,395 million, bringing to $3.2 billion the total raised year-to-date. In 2011, a total of $49 billion was raised, including $36.7 …
Published on 1/23/2012
-
Forma-tive thinking Earnings on deck At least eight profitable biotechs and pharmas are slated to report earnings this week. Nearly all are expected to post positive EPS growth, including a 45% increase by Celgene …
Published on 1/23/2012
-
Ebb & Flow Forma-tive thinking Table: Earnings on deck Figure: Money Raised in 2012 While Forma Therapeutics Holdings LLC has announced two discovery-stage cancer deals with big pharmas this year, the biotech has …
Published on 1/23/2012
-
M&A bounty for VCs The M&A way Investors realized more from acquisitions of private biotechs in 2011 than was invested in private biotechs. The inflows from M&A also outpaced new money raised by biotech VC firms …
Published on 1/23/2012
-
Ebb & Flow Regulatory milestones Allos Therapeutics Inc. (NASDAQ:ALTH) was off $0.15 to $1.51 on Friday after EMA's CHMP recommended against conditional approval of Folotyn pralatrexate to treat relapsed or …
Published on 1/23/2012
-
Ebb & Flow Fast Canaan Canaan Partners has closed a $600 million mixed IT/healthcare fund that took only six months to raise, according to the firm's Brent Ahrens. "Almost every LP came back. We lost a couple that …
Published on 1/16/2012
-
Ebb & Flow Merrimack makes ready Merrimack Pharmaceuticals Inc. set its IPO range last week - the cancer company is hoping to sell 16.7 million shares at $8-$10. A $9 price would raise $150 million and value …
Published on 1/16/2012
-
Ebb & Flow Flagship's enterprise Investors bought into Flagship Ventures' plan to hunt for early stage platform plays, contributing an oversubscribed $270 million to Flagship Ventures Fund IV. The initial target …
Published on 1/16/2012
-
Warping the VC model Money Raised in 2012 Last week, the biotech industry raised $283 million, bringing to $0.8 billion the total raised year-to-date. In 2011, a total of $49 billion was raised, including $36.7 …
Published on 1/16/2012
-
IPO End Around -- A handful of well-financed biotechs with ties to Cougar Biotechnology are taking a road less traveled to the public markets: the Form 10 pathway.
Published on 1/16/2012
-
Ebb & Flow Scottish cash Scottish Equity Partners is moving ahead with its U.K.- and Ireland-focused investments after closing its fourth fund at £200 million ($308.8 million) at the end of 2011. Like previous funds…
Published on 1/16/2012
-
Ebb & Flow Regulatory milestones Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) gained $0.77 to $11.79 last week after the U.K.'s NICE issued a final appraisal determination backing use of once-weekly Bydureon exenatide …
Published on 1/16/2012